SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which takes place September 26-28, 2023, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen’s President and Chief Executive Officer and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in a panel discussion on Tuesday, September 26th, at 8:45 AM ET. Interested parties may access the webcast of the presentation using a link on Exagen’s website at https://investors.exagen.com/events.
About Exagen Inc.
Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.
For more information, please visit Exagen.com and follow @ExagenInc on Twitter.
Investor Relations
Exagen Inc.
Ryan Douglas
This email address is being protected from spambots. You need JavaScript enabled to view it.
760.560.1525
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.27 |
Daily Change: | -0.06 -1.13 |
Daily Volume: | 99,051 |
Market Cap: | US$92.960M |
January 12, 2025 November 14, 2024 November 12, 2024 October 21, 2024 August 05, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load